肺结节病血清生物标志物的研究进展  

Research progress of serum biomarkers in pulmonary sarcoidosis

作　　者：余奇龙 李长毅[2] YU Qilong;LI Changyi(Graduate School of Chongqing Medical University,Chongqing 400016,China;Department of Respiratory Medicine,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学研究生院,重庆400016 [2]重庆医科大学附属第二医院呼吸内科,重庆400010

出　　处：《现代医药卫生》2025年第2期512-517,521,共7页Journal of Modern Medicine & Health

摘　　要：该文综述了近年来肺结节病血清生物标志物的研究进展,依据病理生理机制,将其分类为单核细胞/巨噬细胞相关标志物、T细胞和B细胞活化标志物、急性期反应蛋白及血清钙等几大类。目前,血管紧张素转化酶(ACE)仍是最常用的血清生物标志物,而新型标志物如细胞外溶酶原激活物(CTO)、可溶性白细胞介素-2受体(sIL-2R)及血清钙等也逐渐表现出良好的临床应用前景。尽管这些血清标志物在诊断中存在一定局限性,未来的研究可以通过开发新型生物标志物和探索多种标志物的组合来提高诊断精度,促进肺结节病的早期筛查和个性化治疗的进展。This paper reviewed the research progress of serum biomarkers of pulmonary sarcoidosis in recent years.According to the pathophysiological mechanism,they are classified into monocyte/macrophage related markers,T cell and B cell activation markers,acute phase reaction protein and serum calcium.Currently,angiotensin-converting enzyme(ACE)remains the most widely utilized serum biomarker,while other markers such as cell-free proenzyme activator(CTO),soluble interleukin-2 receptor(sIL-2R),and serum calcium are demonstrating promising clinical applications.Despite certain limitations in the diagnostic use of these serum biomarkers,future research may enhance diagnostic accuracy by developing new biomarkers or investigating combinations of multiple biomarkers,thereby advancing early screening and personalized treatment strategies for pulmonary sarcoidosis.

关 键 词：肺结节病 血清生物标志物 综述 

分 类 号：R563[医药卫生—呼吸系统]